The Dual-Action Weight Loss Medication Patients Keep Asking For

Advertisement

The Dual-Action Weight Loss Medication Patients Keep Asking For

by The HELiXVi Team

Semaglutide targets one hunger pathway. Tirzepatide targets two. That single difference is why so many people now ask for tirzepatide by name. It acts on both the GLP-1 and GIP receptors, and in head to head trial data it has produced some of the largest average weight reductions seen in a weight management medication.

Two switches, not one

GLP-1 and GIP are both gut hormones involved in appetite and blood sugar. By engaging both, tirzepatide can quiet food noise and improve satiety in a way that many people find noticeably stronger. It is the same "the noise stopped" experience people describe with GLP-1 medicine, often turned up a level.

How HELiXVi provides it

You complete a short online assessment, a licensed US provider reviews your health history, and if you qualify, your compounded tirzepatide is prepared by a US state licensed pharmacy and shipped discreetly, with provider support the whole way. You can also talk to our weight loss specialist before you start.

Transparency: compounded tirzepatide is prepared by state licensed pharmacies and is not FDA approved. The decision to prescribe rests with your provider.

See if you qualify in about 2 minutes

Free assessment. No sign up. A licensed provider reviews every plan.

Start My Weight Loss Assessment →

What the research shows

In the SURMOUNT-1 trial published in the New England Journal of Medicine in 2022, adults taking tirzepatide alongside a reduced calorie diet and increased activity lost an average of up to 20.9 percent of their body weight at the 15 mg dose over 72 weeks, compared with 3.1 percent on placebo.

This is published clinical trial data for the tirzepatide molecule, not a HELiXVi patient outcome. Compounded tirzepatide is not FDA evaluated, and individual results vary with starting weight, adherence, diet, and activity.

Check My Eligibility →

This is an advertisement, not editorial content or medical advice. HELiXVi is a telehealth platform and does not manufacture medications. Compounded tirzepatide is prepared by US state licensed pharmacies and is not FDA approved or evaluated for safety, efficacy, or quality. Prescriptions are issued only after an online consultation with an independent licensed provider, and approval is not guaranteed. These statements have not been evaluated by the FDA. Weight loss requires a reduced calorie diet and increased physical activity. Individual results vary.

Start your free consultation right now

No clinic visit. Licensed US clinicians. Dispatched within 24 hours of your consultation and payment.

See the full weight loss program